Citadel Advisors’s Kazia Therapeutics KZIA Stock Holding History

Citadel Advisors’s Portfolio KZIA Stock Details KZIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-200	Closed	-$84K	–	14142
2021 Q4	$84K	Buy	+200	New	+$99.8K	﹤0.01%	12887

Other funds holding KZIA

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Citadel Advisors's KZIA Position: Q4 2024 in Review

Citadel Advisors sold out of Kazia Therapeutics (KZIA) in Q4 2024, closing a stake of 1,210 shares — an estimated $26K sold.

Citadel Advisors first reported a position in KZIA in Q1 2014 and held it in 13 quarters. The position peaked at $202K in Q3 2021. 10 funds tracked by Wall St. Rank hold KZIA as of Q4 2024.

Citadel Advisors reported no remaining Kazia Therapeutics position as of Q4 2024 after selling out during the quarter.
Citadel Advisors sold 1,210 Kazia Therapeutics shares in Q4 2024, an estimated $26K.
Citadel Advisors first reported a position in Kazia Therapeutics in Q1 2014 and held it in 13 quarters.
Citadel Advisors's Kazia Therapeutics position peaked at $202K in Q3 2021.
10 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.